Researchers at Memorial Sloan Kettering Cancer Center have discovered that MEK plays a crucial role in T cell fatigue, a significant hurdle affecting the long-term success of cancer immunotherapy. The research, published in Immunity, indicates that inhibiting MEK allows T cells to preserve energy, sustain activity for extended periods, and potentially enhance the longevity of treatments. The team also highlighted the availability of FDA-approved MEK inhibitors, which could facilitate prompt clinical trials. These insights could lead to the optimization of individualized immunotherapy approaches for various cancer patients.
